SARS-CoV-2 Research Antibodies
SARS-CoV-2 is a virus that causes the acute respiratory syndrome, COVID-19. Research has shown that the virus enters cells by interacting with the host ACE-2 receptor through the SARS-CoV-2 Spike protein Receptor-Binding Domian (RBD). Vaccine and drug discovery has revolved around understanding the interaction between the Spike protein and ACE2 while immunoassay test development has primarily focused on the Nucleocapsid (NP) protein of SARS-CoV-2. To support COVID-19 RnD scientists, Assay genie have developed a range of antibodies including tagged and untagged polyclonal, monoclonal & recombinant antibodies to nanobodies and neutralizing antibodies.
Key Features
- Activity Tested: Comprehensive activity data for neutralizing antiboduies
- Comprehensive Choice: Choose from polyclonal & monoclonal antibodies as well as Nanobodies
- Technologically Advanced: Recombinant and tagged antibodies inlcuded in the range
- Flexible: Tested in multiple applications including ELISA, IF, WB and activity assays
SARS-CoV-2 Spike Protein Antibodies
Product Code | Product Name | Conjugatation | Application |
AGEL2109 | SARS-CoV-2 Spike Protein Monoclonal Antibody [5D9] | Unconjugated | ELISA |
AGEL2110 | SARS-CoV-2 Spike Protein Monoclonal Antibody [D001] | Unconjugated | WB, ELISA |
AGEL2111 | SARS-CoV-2 Spike Protein Monoclonal Antibody [D003] | Unconjugated | WB, ELISA |
AGEL2112 | SARS-CoV-2 Spike S1 Monoclonal Antibody [R007] | Unconjugated | IF, ELISA |
PACOV0001 | SARS-CoV-2 Spike Protein Monoclonal Antibody [H6] | Unconjugated | ELISA, GICA |
PACOV0004 | SARS-CoV-2 Spike Protein Monoclonal Antibody [H6] HRP-conjugated | HRP | ELISA |
PACOV0005 | SARS-CoV-2 Spike Protein Monoclonal Antibody [H6] FITC-conjugated | FITC | ELISA |
PACOV0006 | SARS-CoV-2 Spike Protein Monoclonal Antibody [H6] Biotin-conjugated | Biotin | ELISA |
CAB20017 | SARS-COV-2 Spike Protein Polyclonal Antibody | Unconjugated | IHC, IF, IP, FC, ELISA |
CPAB0418 | SARS-CoV-2 IgG Spike S1 Recombinant Monoclonal Antibody | Unconjugated | ELISA |
CPAB0419 | SARS-CoV-2 IgM Kappa Spike S1 Recombinant Monoclonal Antibody | Unconjugated | ELISA |
SARS-CoV-2 Spike RBD Antibodies
Product Code | Product Name | Conjugatation | Application |
AGEL2113 | SARS-CoV-2 Spike Protein RBD Polyclonal Antibody | Unconjugated | WB, ELISA |
PACOV0003 | SARS-CoV-2 Spike Protein RBD Nanobody [A1] | Unconjugated | ELISA, GICA, Neutralising |
SARS-CoV-2 Spike Neutralizing Antibodies
Product Code | Product Name | Conjugatation | Application |
PACOV0002 | SARS-CoV-2 Spike Protein Neutralizing Monoclonal Antibody [H6] | Unconjugated | ELISA, GICA, Neutralising |
AGEL2120 | SARS-CoV-2 Spike-hIgG1 Neutralizing Antibody | Unconjugated | Neutralization, ELISA |
AGEL2121 | SARS-CoV-2 Spike-mIgG1 Neutralizing Antibody | Unconjugated | Neutralization, ELISA |
AGEL2122 | SARS-CoV-2 S-cIgG1 Neutralizing Antibody | Unconjugated | Neutralization, ELISA |
AGEL2123 | SARS-CoV-2 Spike Neutralizing Antibody | Unconjugated | Neutralization, ELISA |
AGEL2124 | SARS-CoV-2 Spike Neutralizing Antibody (RBD, mFc Tag) | Unconjugated | Neutralization, ELISA |
SARS-CoV-2 Nucleocapsid Antibodies
Product Code | Product Name | Conjugatation | Application |
AGEL2114 | SARS-CoV-2 Nucleocapsid Monoclonal Antibody [6G9] | Unconjugated | ELISA |
AGEL2116 | SARS-CoV-2 Nucleocapsid Monoclonal Antibody [M05] | Unconjugated | WB, ELISA |
AGEL2117 | SARS-CoV-2 Nucleocapsid Monoclonal Antibody [R001] | Unconjugated | WB, ELISA |
PACOV0007 | SARS-CoV-2 Nucleocapsid Monoclonal Antibody [1A6] | Unconjugated | ELISA, GICA |
PACOV0008 | SARS-CoV-2 Nucleocapsid Monoclonal Antibody (WB) [1A6] | Unconjugated | ELISA, WB, GICA |
PACOV0009 | SARS-CoV-2 Nucleocapsid Monoclonal Antibody [1A6] HRP-conjugated | HRP | ELISA |
PACOV0010 | ARS-CoV-2 Nucleocapsid Monoclonal Antibody [1A6] FITC-conjugated | FITC | ELISA |
PACOV0011 | SARS-CoV-2 Nucleocapsid Monoclonal Antibody [1A6] Biotin-conjugated | Biotin | ELISA |
CAB20016 | SARS-COV-2 Nucleocapsid Polyclonal Antibody | Unconjugated | WB, IHC, IF, IP, FC, ELISA |
Anti-ACE2 Antibodies | Human, Mouse & Rat
Product Code | Product Name | Conjugatation | Application |
AGEL2118 | ACE2 Polyclonal Antibody (Human, Mouse, Rat) | Unconjugated | IHC, ELISA |
CAB4612 | ACE2 Rabbit Monoclonal Antibody (Human, Mouse, Rat) | Unconjugated | WB, IHC |
CAB12737 | ACE2 Polyclonal Antibody (Human, Mouse, Rat) | Unconjugated | WB, IHC, IF |
Anti-ACE2 Antibodies | Human
Product Code | Product Name | Conjugatation | Application |
PACO47046 | ACE2 Polyclonal Antibody | Unconjugated | IHC, IF, ELISA |
PACO47047 | ACE2 Antibody, HRP-conjugated | HRP | ELISA |
PACO47048 | ACE2 Antibody, FITC-conjugated | FITC | ELISA |
PACO47049 | ACE2 Antibody, Biotin-conjugated | Biotin | ELISA |
Anti-ACE2 Antibodies | Rat
Product Code | Product Name | Conjugatation | Application |
PACO64123 | ACE2 Polyclonal Antibody | Unconjugated | WB, ELISA |
PACO64124 | ACE2 Antibody, HRP-conjugated | HRP | ELISA |
PACO64125 | ACE2 Antibody, FITC-conjugated | FITC | ELISA |
PACO64126 | ACE2 Antibody, Biotin-conjugated | Biotin | ELISA |
SARS-CoV-2 Information
In-depth research is required to understand and uncover the innate and adaptive immune responses elicited by COVID-19 infection and the immunological and cardiovascular pathways that likely contribute to disease severity. This research will contribute to the development of a vaccine versus the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) and the development of therapeutics and anti-virals to prevent and/or repress SARS-CoV-2 infection. To support COVID-19 research we have developed some key biological research tools including SARS-CoV-2 & ACE 2 Antibodies.
SARS-CoV-2 Spike protein and ACE2 interaction
SARS-CoV-2, the causative viral agent of the disease COVID-19, is a coronavirus which bears the transmembrane glycoprotein spikes (S protein) typical of viruses in its clade. These spikes are a prominent target of human immune responses and have been found to be highly immunogenic. The receptor-binding domain (RBD) of the S protein is particularly targeted by neutralising antibodies.
The spike protein is a heavily-glycosylated, cell-surface protein which mediates viral entry into host cells. The spikes on SARS-CoV-2 allows the virus to enter host cells through the human receptor angiotensin converting enzyme 2 (ACE2), present in alveolar epithelial cells. ACE2, a carboxypeptidase, is part of the renin-angiotensin system (RAS), and has been shown to be a functional receptor of the human coronaviruses SARS-CoV and SARS-CoV-2.The S protein RBD and ACE2 interaction is explained in great detail in this article.
Spike protein is necessary for attachment to susceptible cells. The spike protein is composed of both an S1 domain and S2 domain. S1 contains a receptor-binding domain. The receptor-binding domain of the spike protein mediates an interaction with angiotensin-converting enzyme 2 (ACE2). Neutralising antibody responses, mainly to the Spike protein, begin to develop by week 2 of infection onset and most patients develop neutralising antibodies by week 3.
SARS-CoV-2 Nucleocapsid (N) protein
The time between initial viral exposure and symptom onset is known as the incubation period. For COVID-19, the average incubation period has been reported to be between five and six days, however, there is considerable variation in incubation time.
In patients with SARS-CoV infection, B cell responses are activated firstly against the nucleocapsid (N) protein of SARS-CoV-2. The N protein is one of the most abundant structural proteins during SARS-CoV-2 infection. The role of the N protein is to package the positive strand viral genome RNA into a helical ribonucleocapsid (RNP). The SARS-CoV-2 N protein also plays a role during virion assembly through its interactions with the viral genome and membrane protein M.
Within 4–8 days after symptoms present, antibody responses against the spike (S) protein of the virus are found. Neutralising antibody responses, mainly to the S protein, begin to develop by week 2 of infection onset and most patients develop neutralising antibodies by week 3.
SARS-CoV-2 & ACE 2 Antibodies
To support the efforts of researchers across the globe, ELISA Genie has developed SARS-CoV-2 receptor ACE2 antibodies, spike protein antibodies, nucleoprotein antibodies and more. These antibody research tools will contribute to understanding and combating COVID-19 virus SARS-COV-2 and other coronaviruses.